The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer

Breast Cancer Research and Treatment

Volumn 73, Issue 2, 2002, Pages 135-144

  Moasser, M M ^a   Rosen, Neal ^a,b  

^a Department of Medicine ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

FPTase; FTI; Markers; p53; Ras

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ESTROGEN RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; ISOPROTEIN; MOLECULAR MARKER; MUTANT PROTEIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAS PROTEIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE; TUMOR MARKER;

ACCURACY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; MOLECULAR PROBE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMAN; MOLECULAR PROBES; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; FARNESYLTRANSTRANSFERASE; HUMANS;

EID: 0035991542     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015209123900     Document Type: Article

References (54)

1. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
2. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
3. Peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
4. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units
5. Pharmacokinetics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778123) in solid tumors
6. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
7. A Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
8. A Phase I study of farnesyl transferase inhibitor BMS-214662 in solid tumors
9. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
10. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
11. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
12. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
13. Farnesyltransferase inhibition causes morphological reversion of Ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
14. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides
15. The up-regulation of vascular endothelial growth factor in mutated Ha-Ras HaCaT cell lines is reduced by a famesyltransferase inhibitor
16. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway
17. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
18. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
19. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
20. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers
21. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
22. The type 1 growth factor receptors in human breast cancer
23. EGF receptor expression, regulation, and function in breast cancer
24. HER-2/neu as a predictive marker of response to breast cancer therapy
25. Malignant tumors of the breast
26. Predicting response to cancer chemotherapy: The role of p53
27. p53 and response to chemotherapy and radiotherapy
28. Cancer therapy and p53
29. A phase II study of the farnesyl transferase inhibitor (FTI) SCH 66336 with paclitaxel in patients with solid tumors
30. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
31. Incidence of activating Ras oncogene mutations associated with primary and metastatic human breast cancer
32. The ras gene family and human carcinogenesis
33. The human c-Kirsten Ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB 231
34. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas
35. Comparative study of Harvey-Ras oncogene expression with conventional clinicopathologic parameters of breast cancer
36. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
37. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells
38. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
39. Involvement of caspase family proteases in FPT inhibitor III-induced apoptosis in human ovarian cancer cells
40. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
41. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-Ras transgenic mice
42. In vitro model systems for the study of hormone-dependent human breast cancer
43. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein
44. Human breast carcinoma cells in continuous culture: A review
45. p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons
46. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions
47. Mutations in p 53 as potential molecular markers for human breast cancer
48. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
49. Steroid receptor analyses of nine human breast cancer cell lines
50. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide
51. Mutations in the p 53 gene occur in diverse human tumour types
52. Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma
53. Morphological and biochemical properties of a new human breast cancer cell line